Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis
Ontology highlight
ABSTRACT: GUT103 and GUT108, live biotherapeutic products rationally designed to complement missing or underrepresented functions in the dysbiotic microbiome of IBD patients; they address upstream targets, rather than targeting a single cytokine to block downstream inflammation responses. Systematic colonization experiments in colitis mouse models were performed to test their therapeutic effects. Targeted fecal metabolomics data uploaded here of bile acids, short-chain fatty acids, and tryptophan metabolites provides a unique metabolome perspective for evaluation of the therapeutic potential of GUT103 and GUT108.
ORGANISM(S): Mus Musculus
TISSUE(S): Feces
SUBMITTER: Yunjia Lai
PROVIDER: ST001748 | MetabolomicsWorkbench | Thu Apr 22 00:00:00 BST 2021
REPOSITORIES: MetabolomicsWorkbench
ACCESS DATA